# Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

> **NCT01205685** · PHASE2 · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Hormone-sensitive Metastatic Breast Cancer

## Interventions

- **DRUG:** OSI-906
- **DRUG:** Erlotinib
- **DRUG:** Letrozole
- **DRUG:** Goserelin

## Key facts

- **NCT ID:** NCT01205685
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** PI closed study early, all patients experienced severe toxicities and progressed
- **Last updated:** 2012-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01205685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01205685, "Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01205685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*